Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a China-based company mainly engages in the research and development, production and sales of drugs. The Company is mainly engaged in the research and development, manufacturing and commercialization of innovative drugs in oncology, immunology and other therapeutic fields. The Company's products are antibody-drug conjugates (ADCs) SKB264 and A166. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.

Employees

1,837

Sector

Biotechnology & Medical Research

Calendar

Aug. 31 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-07-11	340.00 $	+1.25%	333,214
25-07-10	335.80 $	-4.00%	371,200
25-07-09	349.80 $	+1.98%	373,200
25-07-08	343.00 $	-2.67%	485,879
25-07-07	352.40 $	-2.65%	330,200

Delayed Quote Hong Kong S.E., July 11, 2025 at 04:08 am EDT

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

340.00HKD

Average target price

330.26HKD

Spread / Average Target

-2.86%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 04:08:03 2025-07-11 am EDT			5-day change	1st Jan Change
340.00 ^HKD	+1.25%		-6.08%	+108.21%

Jun. 12	SKB Biopharma Raises HK$1.94 Billion from Share Placement	MT
Jun. 12	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives A Clinical Trial Notice Approving the Investigational New Drug Application for the Its CLDN18.2-Directed Antibody-Drug Conjugate SKB315 in Combination of the Anti-Programmed Death Ligand 1 (PD-L1) Monoclonal Antibody Tagitanlimab	CI

Capitalization	70.96B 77.7B 9.9B 8.46B 7.88B 7.33B 13.55B 849B 15.06B 94.47B 36.12B 398B 37.13B 36.36B 1,459B	P/E ratio 2025 *	-114x	P/E ratio 2026 *	-827x
Enterprise value	69.57B 76.18B 9.7B 8.3B 7.73B 7.19B 13.28B 833B 14.76B 92.62B 35.41B 390B 36.4B 35.65B 1,430B	EV / Sales 2025 *	35.2x	EV / Sales 2026 *	22.7x
Free-Float	59.59%	Yield 2025 *	-	Yield 2026 *	-

SKB Biopharma Raises HK$1.94 Billion from Share Placement	Jun. 12	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives A Clinical Trial Notice Approving the Investigational New Drug Application for the Its CLDN18.2-Directed Antibody-Drug Conjugate SKB315 in Combination of the Anti-Programmed Death Ligand 1 (PD-L1) Monoclonal Antibody Tagitanlimab	Jun. 12	CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination with Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer	Jun. 11	CI
Sichuan Kelun-Biotech Lung Cancer Combo Gets Breakthrough Tag in China; Shares Slide 3%	Jun. 11	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Results from Phase 1/2 Study of Kelun-Biotech's Trop2 Adc Sacituzumab Tirumotecan	Jun. 10	CI
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC	Jun. 07	CI
SKB Biopharmaceutical Seeks to Raise HK$1.94 Billion from Share Placement; Shares Fall 7%	Jun. 05	MT
Sichuan Kelun-Biotech Biopharmaceutical Placing 5.9 Mln Placing H Shares At HK$331.8 Per Placing H Share	Jun. 04	RE
Accelerated Bookbuild Offering Of H Shares In Sichuan Kelun-Biotech Biopharmaceutical, Term Sheet Shows	Jun. 04	RE
Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. to Present Results from Six Clinical Studies	May. 23	CI
SKB Biopharmaceutical Gets Upfront Payment Under Drug License Contract	May. 23	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives an Upfront Payment from Windward Bio AG	May. 23	CI
Chinese Regulator Accepts SKB Biopharma's New Indication Application for Breast Cancer Drug	May. 22	MT

Jefferies Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$300 from HK$240, Keeps at Buy	Mar. 26	MT
Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy	Feb. 18	MT
Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$195.51 From HK$196.40, Keeps at Buy	24-08-20	MT

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Stock

Equities

6990

CNE1000062J1

Biotechnology & Medical Research

Valuation: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Chart: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Latest news: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Analysts' recommendations: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Press Releases: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

ANNOUNCEMENT OF ANNUAL RESULTS FOR 2024	Mar. 26	PR
Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).	Jan. 11	PR

1 day	+1.25%
1 week	-6.08%
Current month	+3.91%
1 month	-0.87%
3 months	+12.58%
6 months	+105.56%
Current year	+108.21%

1 week	333.8	369.8
1 month	314.2	373.4
Current year	153.9	380
1 year	142	380
3 years	60.6	380
5 years	60.6	380
10 years	60.6	380

Manager	Title	Age	Since
Jun You Ge CEO	Chief Executive Officer	53	2022-02-28
Ze Jian Zhou DFI	Director of Finance/CFO	42	2022-08-16
Xiao Ping Jin CTO	Chief Tech/Sci/R&D Officer	48	2021-09-05

Director	Title	Age	Since
Ge Xin Liu CHM	Chairman	74	2022-02-28
Jun You Ge BRD	Director/Board Member	53	2022-02-24
Si Chuan Liu BRD	Director/Board Member	41	2016-11-21

	2025 *	2026 *
Net sales	1.97B 2.16B 275M 235M 219M 204M 377M 23.62B 419M 2.63B 1B 11.06B 1.03B 1.01B 40.57B	3.06B 3.35B 427M 365M 340M 316M 584M 36.62B 649M 4.07B 1.56B 17.15B 1.6B 1.57B 62.9B
Net income	-612M -670M -85.4M -73.02M -68.02M -63.26M -117M -7.33B -130M -815M -312M -3.43B -320M -314M -12.58B	-76.5M -83.77M -10.67M -9.12M -8.5M -7.91M -14.61M -916M -16.23M -102M -38.94M -429M -40.02M -39.2M -1.57B
Net Debt	-1.39B -1.52B -194M -166M -155M -144M -266M -16.66B -295M -1.85B -708M -7.8B -728M -713M -28.61B	-1.5B -1.64B -209M -178M -166M -155M -286M -17.9B -317M -1.99B -761M -8.38B -782M -766M -30.74B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.25%	-6.08%	+139.10%	-	9.9B
ARGENX SE	-1.01%	+2.87%	+11.77%	+33.47%	34.39B
WUXI APPTEC CO., LTD.	+9.99%	+8.94%	+98.74%	-28.56%	30.84B
BIONTECH SE	-0.90%	+2.63%	+33.28%	-32.19%	27.8B
INSMED INCORPORATED	+1.57%	+0.39%	+27.46%	+321.37%	18.65B
SUMMIT THERAPEUTICS INC.	-3.40%	+1.83%	+188.02%	+2,400.00%	18.57B
WUXI BIOLOGICS (CAYMAN) INC.	+3.70%	+1.72%	+139.66%	-65.41%	13.81B
GENMAB A/S	-1.18%	+6.12%	-23.36%	-44.81%	13.28B
AKESO, INC.	+4.52%	-2.50%	+195.56%	+385.84%	12.94B
EXELIXIS, INC.	-0.69%	-2.80%	+98.94%	+117.45%	12.23B
Average	+1.38%	+2.35%	+90.92%	+343.02%	19.24B
Weighted average by Cap.	+1.62%	+3.74%	+78.56%	+300.57%